Cerus Corporation Announces New Corporate Brand and Global Headquarters

CONCORD, Calif.–(BUSINESS WIRE)–Cerus Corporation (Nasdaq:CERS) announced today a new corporate branding
campaign building upon the Company’s leadership position in helping to
safeguard the world’s blood supply and the planned relocation of its
corporate offices to a new facility in Concord California. The new
facility will consolidate all non-field based, U.S. employees into one
location, facilitating greater teamwork and communication, and allowing
for future expansion as the business grows.

The new corporate brand reflects Cerus’ increasingly important role in
helping blood centers globally to proactively protect the blood supply
against the threat of known and emerging infectious diseases. The
Company aims to be the global leader in pathogen reduction technologies
and a trusted partner of blood centers and hospitals.

“After over two decades of sustained effort to support blood centers and
national transfusion services in adopting our INTERCEPT system as their
standard of care, Cerus is entering the next chapter of our planned
growth and evolution. The new corporate brand and global headquarters
provide Cerus with an improved foundation going forward,” said William
‘Obi’ Greenman, Cerus’ president and chief executive officer. “Since our
inception, as we expanded operations, we grew into three separate
buildings in Concord. The new office provides a scalable workspace to
support our multi-year growth strategy, while our new brand identity
embodies our goal to be a world class partner for an increasing number
of blood centers around the globe.”

Executive, sales administration, finance, and clinical functions are now
located in the new facility. Research and development and regulatory are
expected to relocate later this month.

The new headquarters will be located at 1220 Concord Avenue and occupy
nearly 85,000 square feet compared to the approximately 72,000 square
feet combined in Cerus’ three previous buildings. The site in Concord
was chosen to take advantage of Cerus’ existing presence in the city
which has supported the Company’s growth since the early 1990s and the
location benefits for recruiting talent in the San Francisco Bay Area.

For additional information about Cerus new corporate brand, visit


Cerus Corporation is dedicated solely to safeguarding the world’s blood
supply and aims to become the preeminent global blood products company.
Based in Concord, California, our employees are dedicated to deploying
and suppling vital technologies and pathogen-protected blood components
for blood centers, hospitals and ultimately patients who rely on safe
blood. With the INTERCEPT Blood System, we are focused on protecting
patients by delivering the full complement of reliable products and
expertise for transfusion medicine. Cerus develops and markets the
INTERCEPT Blood System, and remains the only company in the blood
transfusion space to earn both CE Mark and FDA approval for pathogen
reduction of both platelet and plasma components. Cerus currently
markets and sells the INTERCEPT Blood System in the United States,
Europe, the Commonwealth of Independent States, the Middle East and
selected countries in other regions around the world. The INTERCEPT Red
Blood Cell system is in clinical development. For more information about
Cerus, visit www.cerus.com.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus


Tim Lee – Investor Relations Director
Cerus Corporation

error: Content is protected !!